Oxcarbazepine Versus Placebo in Childhood Autism

Completed · Not applicable · Has a placebo group

Conditions studied: Autism

In brief

The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs. placebo in childhood/adolescent autism. This is a twelve-week study involving twenty subjects between the ages of five and seventeen with a diagnosis of autism.

Key facts

Study ID

NCT00467753

Run by

University of Medicine and Dentistry of New Jersey

People needed

5

Starts

2006-04-01

Expected to finish

2011-12-01

Last updated by the study team

2021-01-13

Who can join

Age: 5 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has autism.
• Subject is between five and seventeen years of age
• Subject is not hospitalized.

You may not qualify if…

• Subject has been diagnosed with a psychopathic disorder or a mood disorder, including depression or bipolar disorder.
• Subject has displayed self-injurious behavior.
• Subject has an active seizure disorder or epilepsy.
• Subject has an unstable medical illness.
• Subject has undergone brain injury.
• Subject has a history of diabetes.
• Subject has a history of prior treatment with oxcarbazepine of 600 mg/day for 6 weeks.
• Subject has used other study drugs within the previous 30 days.
• Subject is a pregnant female or unwilling to use acceptable contraception if sexually active.

Where it is running

• Child and Adolescent Psychiatry at the University Behavioral Healthcare Building, UMDNJ-RWJMS — Piscataway, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.